# To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia

> **NCT06622824** · PHASE2,PHASE3 · NOT_YET_RECRUITING · sponsor: **Suzhou Kintor Pharmaceutical Inc,** · enrollment: 756 (estimated)

## Conditions studied

- Androgenetic Alopecia (AGA)

## Interventions

- **DRUG:** KX-826 0.5% BID
- **DRUG:** KX-826 1.0% BID
- **DRUG:** Vehicle (Placebo) applied BID

## Key facts

- **NCT ID:** NCT06622824
- **Lead sponsor:** Suzhou Kintor Pharmaceutical Inc,
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10-15
- **Primary completion:** 2027-10-20
- **Final completion:** 2028-06-30
- **Target enrollment:** 756 (ESTIMATED)
- **Last updated:** 2024-10-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06622824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06622824, "To Evaluate Efficacy and Safety of TopicalKX-826 Solution in Chinese Male Patients With Androgenetic Alopecia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06622824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*